MONTREAL--(BUSINESS WIRE)--Viropro Inc. (OTC BB: VPRO) (“Viropro”) is pleased to announce the signature of an agreement with the National Research Council- Biotechnology Research Institute (NRC-BRI) for the use of powerful inducible expression systems developed and patented by the NRC-BRI. Viropro has obtained a worldwide exclusive licence for the production of the recombinant human interferon beta (<>). Viropro is also planning to sign new licences with NRC-BRI in the near future for the production of other therapeutic human proteins including cytokines and monoclonal antibodies.
